Top

Published in:

01-12-2015 | Review

Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials

Authors: Ying Huang, Wei Chen, Bin S. Teh, E. Brian Butler

Published in: Journal of Radiation Oncology | Issue 4/2015

Abstract

The combination of radiation therapy and immunotherapy is a novel therapeutic approach for prostate cancer. Preclinical evidence has shown that ionizing radiation can have immunostimulatory effects. Ionizing radiation can also affect the tumor microenvironment, enhance infiltration of activated T cells, and trigger an inflammatory process. Together, the combined radio-immunotherapy can enhance cancer cell kill and stimulate the host immune system, providing improved local and systemic control as well as prolongation of survival. The goal of combining radiation therapy with immunotherapy is also to improve cancer cure without an increase in treatment-related toxicity. The combined approach offers a new paradigm, whereby two local therapies, i.e., radiotherapy and in situ immunotherapy, are combined to elicit both local and systemic effects. Herein, we review the rationale for combining radiation and different immunotherapies, the interactions between tumors and the immune system, as well as immunological and abscopal effects of ionizing radiation. The preclinical and clinical trials of combined radiation therapy and immunotherapy for prostate cancer are reviewed. This combined approach holds promise in the management of prostate cancer.

Pollack A, Zagars GK (1997) External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 39(5):1011–1018. doi:10.1016/S0360-3016(97)00508-7 CrossRefPubMed

Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097–1105. doi:10.1016/S0360-3016(02)02829-8 CrossRefPubMed

Zelefsky MJ, Fuks Z, Leibel SA (2002) Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol 12(3):229–237. doi:10.1053/srao.2002.00000 CrossRefPubMed

Hanlon AL, Schultheiss TE, Hunt MA, Movsas B, Peter RS, Hanks GE (1997) Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys 38(1):59–63. doi:10.1016/S0360-3016(97)00234-4 CrossRefPubMed

Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85(11):2460–2468. doi:10.1002/(SICI)1097-0142(19990601)85:11<2460::AID-CNCR23>3.0.CO;2-N CrossRefPubMed

Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu J, Mai W, Huang Y, Floryk D, Ittmann M, Thompson TC, Butler EB, Xu B, Teh BS (2011) The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol 6:39. doi:10.1186/1748-717x-6-39 CrossRefPubMedCentralPubMed

Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC (2003) Therapeutic targets for metastatic prostate cancer. Curr Drug Targets 4(3):251–261CrossRefPubMed

Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10(7):718–726. doi:10.1016/S1470-2045(09)70082-8 CrossRefPubMedCentralPubMed

Demaria S, Bhardwaj N, McBride WH, Formenti SC (2005) Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 63(3):655–666. doi:10.1016/j.ijrobp.2005.06.032 CrossRefPubMedCentralPubMed

10.

Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W (2005) Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11(9):3353–3362. doi:10.1158/1078-0432.ccr-04-2062 CrossRefPubMed

11.

Wersäll PJ, Blomgren H, Pisa P, Lax I, Kälkner K-M, Svedman C (2006) Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 45(4):493–497. doi:10.1080/02841860600604611 CrossRefPubMed

12.

Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW (2014) Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2(9):831–838. doi:10.1158/2326-6066.cir-14-0069 CrossRefPubMed

13.

Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D (2015) The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41(6):503–510. doi:10.1016/j.ctrv.2015.03.011 CrossRefPubMed

14.

Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ, Woo S, Berner B, Smith EO, Oberg KC, Aguilar LK, Thompson TC, Butler EB, Aguilar-Cordova E (2001) Enhanced therapeutic effect of HSV-tk + GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 3(4):536–542. doi:10.1006/mthe.2001.0298 CrossRefPubMed

15.

Teh BS, Aguilar-Cordova E, Vlachaki MT, Aguilar L, Mai WY, Caillouet J, Davis M, Miles B, Kadmon D, Ayala G, Lu HH, Chiu JK, Carpenter LS, Woo SY, Grant 3rd WH, Wheeler T, Thompson TC, Butler EB (2002) Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist 7(5):458–466CrossRefPubMed

16.

Vlachaki MT, Chhikara M, Aguilar L, Zhu X, Chiu KJ, Woo S, Teh BS, Thompson TC, Butler EB, Aguilar-Cordova E (2001) Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys 51(4):1008–1017CrossRefPubMed

17.

Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Ren C, Yang G, Goltsov A, Wang H, Vlachaki MT, Teh BS, Butler EB, Thompson TC (2007) Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther 14(3):227–236. doi:10.1038/sj.gt.3302788 CrossRefPubMed

18.

Fujita T, Satoh T, Timme TL, Hirayama T, Zhu JX, Kusaka N, Naruishi K, Yang G, Goltsov A, Wang J, Vlachaki MT, Teh BS, Brian Butler E, Thompson TC (2014) Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urol Oncol 32(2):92–100. doi:10.1016/j.urolonc.2012.10.007 CrossRefPubMedCentralPubMed

19.

Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, DeWeese TL, Drake CG (2008) Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 68(12):1319–1329. doi:10.1002/pros.20794 CrossRefPubMedCentralPubMed

20.

Wada S, Harris TJ, Tryggestad E, Yoshimura K, Zeng J, Yen HR, Getnet D, Grosso JF, Bruno TC, De Marzo AM, Netto GJ, Pardoll DM, DeWeese TL, Wong J, Drake CG (2013) Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. Int J Radiat Oncol Biol Phys 87(4):769–776. doi:10.1016/j.ijrobp.2013.07.015 CrossRefPubMedCentralPubMed

21.

Teh BS, Aguilar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, Miles B, Kadmon D, Mai WY, Caillouet J, Davis M, Ayala G, Wheeler T, Brady J, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Butler EB (2001) Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer—a preliminary report. Int J Radiat Oncol Biol Phys 51(3):605–613CrossRefPubMed

22.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB (2004) Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer—interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58(5):1520–1529. doi:10.1016/j.ijrobp.2003.09.083 CrossRefPubMed

23.

Fujita T, Teh BS, Timme TL, Mai WY, Satoh T, Kusaka N, Naruishi K, Fattah EA, Aguilar-Cordova E, Butler EB, Thompson TC (2006) Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 65(1):84–90. doi:10.1016/j.ijrobp.2005.11.009 CrossRefPubMed

24.

Satoh T, Teh BS, Timme TL, Mai WY, Gdor Y, Kusaka N, Fujita T, Pramudji CK, Vlachaki MT, Ayala G, Wheeler T, Amato R, Miles BJ, Kadmon D, Butler EB, Thompson TC (2004) Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 59(2):562–571. doi:10.1016/j.ijrobp.2004.01.020 CrossRefPubMed

25.

Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J, DePeralta-Venturina M, Xia X, Brown S, Lu M, Kim JH (2003) Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63(21):7497–7506PubMed

26.

Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4(1):11–22. doi:10.1038/nrc1252 CrossRefPubMed

27.

Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360. doi:10.1146/annurev.immunol.22.012703.104803 CrossRefPubMed

28.

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (New York, NY) 331(6024):1565–1570. doi:10.1126/science.1203486 CrossRef

29.

Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213:131–145. doi:10.1111/j.1600-065X.2006.00442.x CrossRefPubMed

30.

Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J (2011) Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 23(2):286–292. doi:10.1016/j.coi.2010.11.013 CrossRefPubMedCentralPubMed

31.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998. doi:10.1038/ni1102-991 CrossRefPubMed

32.

Watts C (2004) The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat Immunol 5(7):685–692. doi:10.1038/ni1088 CrossRefPubMed

33.

Rock KL, Goldberg AL (1999) Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17:739–779. doi:10.1146/annurev.immunol.17.1.739 CrossRefPubMed

34.

Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273CrossRefPubMed

35.

Ferris RL, Jaffee EM, Ferrone S (2010) Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol Off J Am Soc Clin Oncol 28(28):4390–4399. doi:10.1200/jco.2009.27.6360 CrossRef

36.

Levy A, Chargari C, Cheminant M, Simon N, Bourgier C, Deutsch E (2013) Radiation therapy and immunotherapy: implications for a combined cancer treatment. Crit Rev Oncol Hematol 85(3):278–287. doi:10.1016/j.critrevonc.2012.09.001 CrossRefPubMed

37.

Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P (2014) Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer 2:14. doi:10.1186/2051-1426-2-14 CrossRefPubMedCentralPubMed

38.

Zitvogel L, Kepp O, Kroemer G (2010) Decoding cell death signals in inflammation and immunity. Cell 140(6):798–804. doi:10.1016/j.cell.2010.02.015 CrossRefPubMed

39.

Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3(1):23–35. doi:10.1038/nri978 CrossRefPubMed

40.

Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122(3):787–795. doi:10.1172/jci59643 CrossRefPubMedCentralPubMed

41.

Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22(4):275–281. doi:10.1016/j.semcancer.2012.01.011 CrossRefPubMedCentralPubMed

42.

Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014–1022. doi:10.1038/ni.2703 CrossRefPubMedCentralPubMed

43.

Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450(7171):903–907. doi:10.1038/nature06309 CrossRefPubMed

44.

Demaria S, Golden EB, Formenti SC (2015) Role of local radiation therapy in cancer immunotherapy. JAMA Oncology. doi:10.1001/jamaoncol.2015.2756 PubMed

45.

Eriksson D, Stigbrand T (2010) Radiation-induced cell death mechanisms. Tumour Biol 31(4):363–372. doi:10.1007/s13277-010-0042-8 CrossRefPubMed

46.

Gudkov AV, Komarova EA (2003) The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3(2):117–129. doi:10.1038/nrc992 CrossRefPubMed

47.

Ferrara TA, Hodge JW, Gulley JL (2009) Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther 11(1):37–42PubMedCentralPubMed

48.

Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC (2012) The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2:88. doi:10.3389/fonc.2012.00088 CrossRefPubMedCentralPubMed

49.

McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, Dougherty GJ, Iwamoto KS, Pervan M, Liao YP (2004) A sense of danger from radiation. Radiat Res 162(1):1–19CrossRefPubMed

50.

Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105(4):256–265. doi:10.1093/jnci/djs629 CrossRefPubMedCentralPubMed

51.

Formenti SC, Demaria S (2012) Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 84(4):879–880. doi:10.1016/j.ijrobp.2012.06.020 CrossRefPubMed

52.

Shiao SL, Coussens LM (2010) The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 15(4):411–421. doi:10.1007/s10911-010-9194-9 CrossRefPubMedCentralPubMed

53.

Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203(5):1259–1271. doi:10.1084/jem.20052494 CrossRefPubMedCentralPubMed

54.

Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, et al. (1994) Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1(5):357–364CrossRefPubMed

55.

Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H (2004) Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther 11(10):665–680. doi:10.1038/sj.cgt.7700741 CrossRefPubMed

56.

Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64(12):4328–4337. doi:10.1158/0008-5472.can-04-0073 CrossRefPubMed

57.

Yoshimura M, Itasaka S, Harada H, Hiraoka M (2013) Microenvironment and radiation therapy. BioMed Res Int 2013:685308. doi:10.1155/2013/685308 CrossRefPubMedCentralPubMed

58.

Golden EB, Formenti SC (2014) Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Oncoimmunology 3(1):e28133. doi:10.4161/onci.28133 CrossRefPubMedCentralPubMed

59.

Thompson RF, Maity A (2014) Radiotherapy and the tumor microenvironment: mutual influence and clinical implications. Adv Exp Med Biol 772:147–165. doi:10.1007/978-1-4614-5915-6_7 CrossRefPubMed

60.

Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM (2008) Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180(5):3132–3139CrossRefPubMed

61.

Matsumura S, Demaria S (2010) Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res 173(4):418–425. doi:10.1667/rr1860.1 CrossRefPubMedCentralPubMed

62.

Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW (2004) Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64(21):7985–7994. doi:10.1158/0008-5472.can-04-1525 CrossRefPubMed

63.

Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW (2003) Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170(12):6338–6347CrossRefPubMed

64.

Gasser S, Orsulic S, Brown EJ, Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436(7054):1186–1190. doi:10.1038/nature03884 CrossRefPubMedCentralPubMed

65.

Ohba K, Omagari K, Nakamura T, Ikuno N, Saeki S, Matsuo I, Kinoshita H, Masuda J, Hazama H, Sakamoto I, Kohno S (1998) Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 43(4):575–577CrossRefPubMedCentralPubMed

66.

Nam SW, Han JY, Kim JI, Park SH, Cho SH, Han NI, Yang JM, Kim JK, Choi SW, Lee YS, Chung KW, Sun HS (2005) Spontaneous regression of a large hepatocellular carcinoma with skull metastasis. J Gastroenterol Hepatol 20(3):488–492. doi:10.1111/j.1440-1746.2005.03243.x CrossRefPubMed

67.

Mole RH (1953) Whole body irradiation; radiobiology or medicine? Br J Radiol 26(305):234–241. doi:10.1259/0007-1285-26-305-234 CrossRefPubMed

68.

Ishiyama H, Teh BS, Ren H, Chiang S, Tann A, Blanco AI, Paulino AC, Amato R (2012) Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier? Clin Genitourin Cancer 10(3):196–198. doi:10.1016/j.clgc.2012.01.004 CrossRefPubMed

69.

Rees GJ, Ross CM (1983) Abscopal regression following radiotherapy for adenocarcinoma. Br J Radiol 56(661):63–66. doi:10.1259/0007-1285-56-661-63 CrossRefPubMed

70.

Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S (2007) In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 204(2):345–356. doi:10.1084/jem.20061890 CrossRefPubMedCentralPubMed

71.

Breart B, Lemaitre F, Celli S, Bousso P (2008) Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest 118(4):1390–1397. doi:10.1172/jci34388 CrossRefPubMedCentralPubMed

72.

Drake CG (2012) Combination immunotherapy approaches. Ann Oncol 23(Suppl 8):viii41–viii46. doi:10.1093/annonc/mds262 CrossRefPubMed

73.

Kamrava M, Bernstein MB, Camphausen K, Hodge JW (2009) Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the three musketeers or just another quixotic combination? Mol BioSyst 5(11):1262–1270. doi:10.1039/b911313b CrossRefPubMed

74.

Kwilas AR, Donahue RN, Bernstein MB, Hodge JW (2012) In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2:104. doi:10.3389/fonc.2012.00104 CrossRefPubMedCentralPubMed

75.

Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, von Boehmer L, van den Broek M (2013) Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clin Cancer Res 19(17):4843–4853. doi:10.1158/1078-0432.ccr-13-0352 CrossRefPubMed

76.

Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SL, Thompson TC (1996) Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7(4):515–523. doi:10.1089/hum.1996.7.4-515 CrossRefPubMed

77.

Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC (1997) Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 70(2):183–187CrossRefPubMed

78.

Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3(2):133–146. doi:10.1038/nri1001 CrossRefPubMed

79.

Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC (2014) Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 4:325. doi:10.3389/fonc.2014.00325 CrossRefPubMedCentralPubMed

80.

Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565–594. doi:10.1146/annurev.immunol.19.1.565 CrossRefPubMed

81.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.1056/NEJMoa1200690 CrossRefPubMedCentralPubMed

82.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134–144. doi:10.1056/NEJMoa1305133 CrossRefPubMedCentralPubMed

83.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465. doi:10.1056/NEJMoa1200694 CrossRefPubMedCentralPubMed

84.

Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60(9):2444–2448PubMed

85.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422. doi:10.1056/NEJMoa1001294 CrossRefPubMed

86.

Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM (2013) Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 24(7):1813–1821. doi:10.1093/annonc/mdt107 CrossRefPubMedCentralPubMed

87.

Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700–712. doi:10.1016/s1470-2045(14)70189-5 CrossRefPubMedCentralPubMed

Title: Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials
Authors: Ying Huang
Wei Chen
Bin S. Teh
E. Brian Butler
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 4/2015
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-015-0240-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Combined radiotherapy and immunotherapy–a new promising treatment approach in oncology

Dose-volume relationship of acute and late small bowel toxicity from radiation therapy for prostate cancer: a Veterans Affairs study

Radiation with immunotherapy: an emerging combination for cancer treatment

Radiotherapy and the abscopal effect: insight from the past, present, and future

Long-term outcome of a phase II trial using immunomodulatory in situ gene therapy in combination with intensity-modulated radiotherapy with or without hormonal therapy in the treatment of prostate cancer

The role of combined radiation and immunotherapy in breast cancer treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer